LARP1 EGYR Peptide Quantification for Reliable Cancer Monitoring

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting LARP1 protein in biological samples, particularly blood samples, are unreliable due to protein fragmentation leading to unpredictable level changes over time, and there is a need for improved detection and quantification methods.

Innovation Solution

The method involves digesting biological samples with trypsin to release the LARP1-derived EGYR peptide, which is then detected and quantified using mass spectrometry, with optional chromatographic separation and the use of isotopically labeled peptide standards to generate a standard curve for accurate quantitation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Sandwich ELISA is used to detect LARP1 in circulation, then detection can be performed, but the levels are unpredictable and change over time due to protein fragmentation

Engineering Contradiction:

Improvedetection reliabilityVSAvoidmeasurement precision

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent segments the LARP1 protein into a specific peptide fragment (EGYR sequence) for detection. By focusing on a particular peptide segment rather than the entire protein, the method achieves more reliable and precise measurements, as the peptide fragment is more stable and less prone to fragmentation issues compared to the full protein in circulation.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent extracts and isolates the EGYR peptide fragment from the complex mixture of proteins in biological samples. This extraction process allows for specific detection of the LARP1-derived peptide without interference from other proteins, thereby improving both the reliability and precision of LARP1 detection over time.

Inventive Principle:

Principle #2Taking out (Extraction)

2Measurement precision

If mass spectrometry is used to detect EGYR peptide, then detection precision is improved, but device complexity increases

Engineering Contradiction:

Improvequantification precisionVSAvoiddetection system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses an intermediary approach by detecting a peptide fragment (EGYR) as a surrogate marker for the full LARP1 protein. This intermediary peptide can be more reliably detected and quantified using mass spectrometry, providing precise measurement of LARP1 levels without requiring direct analysis of the complex full protein.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Measurement precision

If protein digestion is performed to release EGYR peptide, then detection accuracy is improved, but loss of time is required for the digestion process

Engineering Contradiction:

Improvedetection accuracyVSAvoidsample processing time

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent employs preliminary action by pre-digesting protein samples with trypsin to release the EGYR peptide fragment before detection. This preliminary digestion step ensures that the peptide is already in its detectable form when analysis begins, improving detection accuracy while the time required can be optimized through protocol development and standardization.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for precise detection and quantification of LARP1 protein levels, enabling monitoring of cancer progression, treatment efficacy, and early cancer detection by accurately determining the presence and amount of EGYR peptide in samples.

Implementation Method 1

digesting biological samples with trypsin to release the LARP1-derived EGYR peptide

Methodology Applied

Scientific EffectProteolytic digestion: Enzyme

Implementation Method 2

detected and quantified using mass spectrometry

Methodology Applied

Scientific EffectMass spectrometry: Ionisation

Implementation Method 3

with optional chromatographic separation

Methodology Applied

Scientific EffectChromatographic separation: Chromatography

Data Source

PatentUS20260036586A1Detection of LARP1

Publication Date: 2026.02.05 LTD PRENOSTICS

AI summary

The invention relates to the detection of EGYR peptide in a biological sample as a measure of the presence and/or amount of LARP1 protein in the sample. Suitably, the invention relates to methods for quantitative measurement of LARP1 and LARP1-derived EGYR peptide by chromatography-tandem mass spectrometry. The invention also relates to peptide standards and their use in quantitative mass spectrometric analyses. The ability to detect the amount of LARP1 in a biological sample has application in detecting and monitoring cancer.